In 2018, Chinese companies made more than 150 cross-border life sciences licensing deals, with the average upfront payment of ~$10 Million, having reached a record high. Over 40% of early- and late-stage assets entered China market through licensing deals.
In this win-win scene, Chinese companies are on the hunt for innovative assets they can develop and/or commercialize in the emerging China healthcare market. Such partnerships, in return, provide a vital route for foreign companies into a country that can otherwise be hard to penetrate.
The trend remains for 2019:
- In April, Shanghai-based Everest Medicines set a record when it agreed to pay $835 million agreement for China rights to an ADC cancer drug from Immunomedics.
- In May, Nanjing-based NJCTTQ Signs $4 billion in-licensing deal for bi-specific immunotherapies from Abpro Therapeutics
- In November, Hengrui Medicine agreed to pay up to $165 million for China right to Novaliq Dry Eye Treatments
New for 2020 Company Presentation Track: Gain Insights on Dealmaking by Hearing Real-World Case Studies
6 executives who have closed rounds from Chinese investors, or deals with Chinese companies will share their success stories and experience, followed by Q&A with the audience.
- Fundraising: Zhenhua Wu, CEO, Exegenesis Bio
- Licensing Deal:
Feng Tian, CEO, Ambrx
Ambrx and BeiGene collaborate on next generation biologics
David Poon, VP of Business Development, Zymeworks
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
Anu Balendran, VP of Business Development, Alligator Bioscience
Alligator Bioscience Signs Antibody Agreement for Greater China
James Lee, Senior Business Development Manager, Atomwise
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery
- Distribution Partnership:
Darrin Crisitello, chief commercial officer, Mission Bio
Mission Bio Launches in China, Announces Distribution Partnership with Novogene
The presenting slots are filled up rapidly. Start your China partnering journey now!
In order to help you better understand China Focus conference and company presentation opportunity, we will hold “Everything you need to know about China Focus” live webinar. Join us to know:
- What China Focus can bring to you
- What’s unique about presenting at China Focus
- What’s the process of company presentation
Date & Time: Dec 18, 2019 8:00 PM in Central Time (US and Canada)
Duration: 1 hour
Speaker: Miao Guo Smith, MBA, VP, Operations
Dr. Ginger Ding, Director, Investment Analyst
Register for FREE today!
|Save Your Slot|
During the 2020 JP Morgan Healthcare Conference, GenScript Biotech Global Forum will be taking place on, January 14, at Grand Hyatt San Francisco, U.S.
Under the theme of “Cell & Gene Therapy and Booming China Market”, the conference aims to build a bridge between the cell & gene therapy industry and capital community, accelerating the mutual understanding and creating collaboration opportunities worldwide.
Registration fee: $50.
Please click here for more information.